



# Preliminary data on safety and effectiveness of six-month all-oral regimens in patients with rifampicin-resistant tuberculosis in Belarus

**Natalia Yatskevich**<sup>1</sup>, Henadz Hurevich<sup>1</sup>, Varvara Solodovnikova<sup>1</sup>, Ekaterine Garsevanidze<sup>2</sup>, Nathalie Lachenal<sup>3</sup>, Jose Luis Alvarez<sup>4</sup>, Norman Sitali<sup>5</sup>, Animesh Sinha<sup>4</sup>, Alena Skrahina<sup>1</sup>

<sup>1</sup>Republican Scientific and Practical Center for Pulmonology and Tuberculosis, Minsk, Belarus;

<sup>2</sup>Médecins Sans Frontières (MSF), Minsk, Belarus;

<sup>3</sup>MSF, Geneva, Switzerland;

<sup>4</sup>MSF, London, UK;

<sup>5</sup>MSF, Berlin, Germany

# Introduction

The duration of treatment for rifampicin-resistant tuberculosis (RR-TB) in Belarus prior to December 2022 was 18-20 months.

The efficacy of treatment was around 73% in 2018.

The development of shorter regimens is urgent.

Six-month treatment regimens are used under operational research (OR) conditions in Belarus since February 2022.

## Aim:

to evaluate safety and effectiveness of six-month all-oral regimens in patients with RR-TB.





# **Methods**

#### **Prospective study:**

- BPaLM: 24<sub>weeks</sub>Bdq-Pa-Lzd<sub>600->300</sub>-Mfx
- BPaLC: 24<sub>weeks</sub>Bdq-Pa-Lzd<sub>600->300</sub>-Cfz \*
- \* resistance to Mfx

#### **Assessments:**

- Treatment outcomes,
- time to culture conversion,
- time to adverse event (AE) occurrence,
- AE types, frequency, outcomes.
- Univariate analysis factors associated with unfavourable treatment outcome.

## **Drugs:**

- Bdq Bedaquiline,
- Pa Pretomanid,
- Lzd Linezolid,
- Mfx Moxifloxacin,
- Cfz Clofazimine

## **Ethics.**


This study was approved by

- the MSF Ethics Review Board (ERB)
- the Belarus Independent ERB.





# **Enrolment flow diagram**






# Characteristics of patients, BPaLM/C, n=176

Characteristics	BPaLM cohort n=112	BPaLC cohort n=64	P value
Age, Median (25; 75 percentile)	47 (37; 55)	41 (34; 55)	0.002
Male/Female	86 (77%) / 26 (23%)	47 (73%) / 17 (27%)	> 0.05
BMI < 18,5 kg/m <sup>2</sup>	15 (13%)	10 (16%)	> 0.05
Previously treated	25 (22%)	17 (27%)	> 0.05
Characteristics of TB process			
Bilateral X-ray changes	36 (32%)	22 (34%)	> 0.05
Cavitary lesion	39 (35%)	20 (31%)	> 0.05
Sputum smear positive	33 (29%)	19 (30%)	> 0.05





# **Characteristics of patients, BPaLM/C, n=176**



## **BPaLM**, **n=112**

## BPaLC, n=64


\* p = 0.02





## **Results**

**Primary outcome** 






# **BPaLM/C safety profile, n=177**

**BPaLM**, n=112

7% of patients in BPaLM, 9% of patients in BPaLC cohorts had serious adverse event (SAE)

SAE





## BPaLC, n=65






# **BPaLM/C safety profile, n=177**





#### **SAE outcomes**




**BPaLM/C** 

Median time to the first SAE occurrence was 92.5 (IQR, 12.5-143) days






## Predictors of unfavourable treatment outcome, BPaLM/C, n=176



#### Odds Ratio for unfavourable treatment outcome







# Conclusions

• High treatment success BPaLM – 93.8%,

BPaLC – 92.2%.

- Good safety profile
  - Low frequency of SAE (7% BPaLM, 9% BPaLC).
  - SAE rarely led to medicines withdrawal.
- Proper monitoring and management of AE is an essential component.
- The results will be implemented into programmatic conditions.





# Acknowledgements

- Thanks to all operational research participants,
- Doctors Without Borders (Médecins Sans Frontières (MSF),
- WHO regional office for Europe and WHO Country Office in Belarus,
- Global Fund to Fight AIDS, Tuberculosis and Malaria,
- NTP, regional monitors,
- Staff of the Republican Scientific and Practical Center for Pulmonology and Tuberculosis, Minsk,
- Staff of all Tuberculosis clinics and outpatient departments in Belarus.



